First-in-Human Clinical Results Published in The Journal of Clinical Pharmacology and Presented at WCP2026
T-E Pharma’s subsidiary, Immunwork, Inc., announced that the First-in-Human (FIH) Phase 1/2a clinical study results of TE-8105, a long-acting GLP-1 receptor agonist developed using Immunwork’s proprietary technology platform, have been published in the internationally recognized journal The Journal of Clinical Pharmacology. The publication, entitled “First-in-human study of a long-acting GLP-1 receptor agonist (TE-8105) in overweight or obese adults without type 2 diabetes mellitus,” reports the clinical pharmacology and safety findings of TE-8105. The study was also selected for presentation at the 20th World Congress of Basic and Clinical Pharmacology 2026 (WCP2026), a leading international conference in basic and clinical pharmacology. The TE-8105 Phase 1/2a results were shared through an invited scientific presentation and poster session, further highlighting the clinical development potential of TE-8105.
Dual Recognition from an International Journal and Global Scientific Congress Highlights the Clinical Potential of TE-8105
The Journal of Clinical Pharmacology, an internationally recognized journal in clinical pharmacology and drug development, publishes research covering pharmacokinetics (PK), pharmacodynamics (PD), safety evaluation, and first-in-human studies. The 20th WCP2026 is a leading global congress bringing together experts in pharmacology, clinical development, and translational medicine. At WCP2026, Dr. Thomas M. Polasek, Principal Investigator of the TE-8105 clinical trial, was invited to present the first-in-human study results and clinical pharmacology profile of TE-8105. The long-acting potential of TE-8105 attracted strong interest from attendees, who recognized its potential to enable less frequent subcutaneous dosing compared with current GLP-1 receptor agonists. These findings highlight the innovative advantages and clinical development potential of TE-8105, with its research achievements recognized by both an international peer-reviewed journal and a global scientific platform.
First-in-Human Study Demonstrates Long-Acting Profile, Favorable Safety, and Weight Loss Potential of TE-8105
TE-8105 was developed using Immunwork’s proprietary “Fatty Acid Bundle Platform”, which conjugates a modified GLP-1 molecule with a fatty acid bundle to extend its duration of action. The Phase 1/2a clinical study demonstrated an average plasma half-life of approximately 120 hours (about 5 days), supporting the potential for less frequent dosing and improved treatment convenience. TE-8105 showed a favorable safety and tolerability profile. Treatment-related adverse events were mainly mild gastrointestinal symptoms commonly associated with GLP-1 therapies, including nausea, abdominal pain, constipation, and vomiting, with no drug-related serious adverse events observed. Preliminary efficacy results showed trends toward body weight reduction and improvements in metabolic parameters, with some participants achieving clinically meaningful weight loss, supporting the potential of TE-8105 as a promising long-acting GLP-1 therapy for obesity and related metabolic diseases.
Rapidly Growing GLP-1 Market Expands Opportunities for TE-8105 to Address Global Metabolic Disease Burden
GLP-1 receptor agonists have transformed the treatment landscape for obesity and type 2 diabetes mellitus (T2DM), with expanding applications in cardiovascular disease, chronic kidney disease, metabolic dysfunction-associated steatohepatitis (MASH), obstructive sleep apnea (OSA), and other metabolic disorders. According to Grand View Research, the global GLP-1 weight loss drug market is projected to grow from approximately US$13.84 billion in 2024 to US$48.84 billion by 2030, representing a compound annual growth rate (CAGR) of approximately 18.5%. When including all anti-obesity medications, the market is expected to exceed US$77 billion by 2030, highlighting the continued growth potential of the global metabolic disease therapeutics market.
Phase 2b Clinical Trial of TE-8105 to Initiate in Australia and Taiwan, Advancing Global Clinical Development Strategy
The international publication of TE-8105 clinical results and presentation at WCP2026 further demonstrate Immunwork’s innovation capabilities in long-acting peptide therapeutics and strengthen the global visibility of TE-8105 for future partnerships and licensing opportunities. The Phase 2b clinical trial of TE-8105 is planned to initiate in Australia and Taiwan in Q4 2026 to evaluate optimized dosing strategies, efficacy, safety, and metabolic improvements in individuals with obesity, while exploring additional indications including T2DM and MASH. Immunwork will continue advancing TE-8105 toward a next-generation long-acting GLP-1 therapy, aiming to provide a more convenient and effective treatment option for patients with obesity and metabolic diseases worldwide.
References (Immunwork’s Research Publications on TE-8105)：
1. First-in-Human Clinical Study of TE-8105 (Journal of Clinical Pharmacology) https://accp1.onlinelibrary.wiley.com/doi/10.1002/jcph.70224
2. Development of TE-8105 as a Long-Acting GLP-1 RA (Journal of Medicinal Chemistry) https://doi.org/10.1021/acs.jmedchem.4c02153
3. Sublingual Formulation Development of TE-8105 (International Journal of Pharmaceutics) https://doi.org/10.1016/j.ijpharm.2026.126752
Media Coverage
Tech Times: “Biweekly GLP-1 Drug Clears First Human Test via Dual Fatty Acid Engineering” August 5, 2026